banner2

Getting started
Pomalidomide CAS 19171-19-8

Pomalidomide CAS 19171-19-8 - China Manufacturers, Factory, Suppliers

Pomalidomide CAS 19171-19-8, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

3-Nitrophthalimide CAS 603-62-3 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 3-Nitrophthalimide CAS 603-62-3 Purity >99.0% (HPLC)
Read More

3-Nitrophthalic Anhydride CAS 641-70-3 Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 3-Nitrophthalic Anhydride CAS 641-70-3 Pomalidomide Intermediate Purity >98.0% (HPLC)

2,6-Dioxopiperidine-3-Ammonium Chloride CAS 24666-56-6 Purity 99.0 (HPLC) Lenalidomide Intermediate Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — 3-Aminopiperidine-2,6-Dione Hydrochloride CAS 24666-56-6; 2686-86-4 Purity >99.0% Lenalidomide Intermediate Factory

Trimagnesium Dicitrate Nonahydrate CAS 153531-96-5 Magnesium (Mg) 14.5%~16.4%

Saccharin Insoluble CAS 81-07-2 Purity >99.0% (HPLC)

2,3-Butanedione CAS 431-03-8 Purity >99.0% (GC)

Citric Acid Anhydrous CAS 77-92-9 Assay 99.5~100.5%

banner1

Top Selling Products

Related Blog
Reviews

Method Of Analyzing Palladium Content In Palladium Catalysts

1. Abstract Enrichment palladium of palladium catalysts by pyrometallurgy, then dissolve the palladium in admixture acid, the liquid is analyzed by AAS. 2. Reagent 2.1 Hydrochloric acid(ρ1.19g/ml) ...
Yellow phosphorus and phosphoric acid rose together

Yellow phosphorus and phosphoric acid rose together Yunnan-guizhou yellow phosphorus prices rose.Data show that the offer of 34500 yuan/ton at the beginning of the week has risen to 60,000 yuan/to...
The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...

2022.10.19 02:51:47
2022.04.13 17:23:28
2022.04.08 17:39:10
2022.04.06 21:10:09
2022.01.15 03:37:24
2021.10.16 02:42:12

related search